408 related articles for article (PubMed ID: 31576686)
1. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients.
Mitsuhashi A; Habu Y; Kobayashi T; Kawarai Y; Ishikawa H; Usui H; Shozu M
J Gynecol Oncol; 2019 Nov; 30(6):e90. PubMed ID: 31576686
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
[TBL] [Abstract][Full Text] [Related]
3. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
Mitsuhashi A; Kawasaki Y; Hori M; Fujiwara T; Hanaoka H; Shozu M
BMJ Open; 2020 Feb; 10(2):e035416. PubMed ID: 32114477
[TBL] [Abstract][Full Text] [Related]
4. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
Yang BY; Gulinazi Y; Du Y; Ning CC; Cheng YL; Shan WW; Luo XZ; Zhang HW; Zhu Q; Ma FH; Liu J; Sun L; Yu M; Guan J; Chen XJ
BJOG; 2020 Jun; 127(7):848-857. PubMed ID: 31961463
[TBL] [Abstract][Full Text] [Related]
5. New therapeutic approaches for the fertility-sparing treatment of endometrial cancer.
Mitsuhashi A; Shozu M
J Obstet Gynaecol Res; 2020 Feb; 46(2):215-222. PubMed ID: 32017321
[TBL] [Abstract][Full Text] [Related]
6. [The long-term efficacy of metformin in megestrol acetate-based fertility-sparing treatment for patients with endometrial atypical hyperplasia and endometrioid endometrial cancer].
Dong YT; Guan J; Yang BY; Yierfulati G; Xue Y; Chen XJ
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(10):729-735. PubMed ID: 38462352
[No Abstract] [Full Text] [Related]
7. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
Zhou R; Yang Y; Lu Q; Wang J; Miao Y; Wang S; Wang Z; Zhao C; Wei L
Gynecol Oncol; 2015 Dec; 139(3):424-8. PubMed ID: 26428941
[TBL] [Abstract][Full Text] [Related]
8. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
[TBL] [Abstract][Full Text] [Related]
9. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
Acosta-Torres S; Murdock T; Matsuno R; Beavis AL; Stone RL; Wethington SL; Levinson K; Grumbine F; Ferriss JS; Tanner EJ; Fader AN
Gynecol Oncol; 2020 May; 157(2):348-356. PubMed ID: 32085863
[TBL] [Abstract][Full Text] [Related]
10. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
Yang B; Xu Y; Zhu Q; Xie L; Shan W; Ning C; Xie B; Shi Y; Luo X; Zhang H; Chen X
Gynecol Oncol; 2019 Apr; 153(1):55-62. PubMed ID: 30674421
[TBL] [Abstract][Full Text] [Related]
11. The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Guan J; Chen XJ
Front Endocrinol (Lausanne); 2022; 13():1041535. PubMed ID: 36387903
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.
Chae-Kim J; Garg G; Gavrilova-Jordan L; Blake LE; Kim TT; Wu Q; Hayslip CC
Int J Gynecol Cancer; 2021 Dec; 31(12):1499-1505. PubMed ID: 34785524
[TBL] [Abstract][Full Text] [Related]
13. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
[TBL] [Abstract][Full Text] [Related]
14. Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis.
Shao F; Li Y; Zhao Y
Front Endocrinol (Lausanne); 2023; 14():1139858. PubMed ID: 37415671
[TBL] [Abstract][Full Text] [Related]
15. Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology.
Ushijima K; Tsuda N; Yamagami W; Mitsuhashi A; Mikami M; Yaegashi N; Enomoto T
J Gynecol Oncol; 2023 May; 34(3):e38. PubMed ID: 36659833
[TBL] [Abstract][Full Text] [Related]
16. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
Gong Q; Chen X; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy.
Ga H; Taguchi A; Honjoh H; Nishijima A; Eguchi S; Miyamoto Y; Sone K; Mori M; Osuga Y
Arch Gynecol Obstet; 2023 Nov; 308(5):1629-1634. PubMed ID: 37310452
[TBL] [Abstract][Full Text] [Related]
18. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
[TBL] [Abstract][Full Text] [Related]
19. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
20. Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review.
Murakami I; Machida H; Morisada T; Terao Y; Tabata T; Mikami M; Hirashima Y; Kobayashi Y; Baba T; Nagase S
J Gynecol Oncol; 2023 Jul; 34(4):e49. PubMed ID: 36929578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
